Getting your Trinity Audio player ready...

Several stocks are currently undergoing noteworthy developments, making them worthy of closer monitoring. This feature will delve into five stocks that merit inclusion in watch lists, offering insight into their potential.

Catheter Precision (NYSE American: VTAK), a leading technology firm specializing in state-of-the-art electrophysiology techniques for treating cardiac arrhythmias, introduced its LockeT suture closure device at the upcoming International Symposium on Left Atrial Appendage, scheduled for March 1-2, 2024, at the Intercontinental New York Times Square. This event is poised to draw worldwide attention and provide essential education for healthcare professionals in cardiology, electrophysiology, and internal medicine. Additionally, Catheter Precision Inc. showcased its latest innovations at the AF Symposium conference held from February 1-3, 2024, in Boston, Massachusetts. Notably, the company recently announced its successful partnership with a new distributor for its VIVO product in the Turkish market on January 25, 2024. Furthermore, on January 22, 2024, Catheter Precision revealed a distribution agreement for its LockeT product in Brazil with another distributor.

Telesis Bio Inc. (NASDAQ: TBIO) emerges as a prominent provider of RNA and DNA solutions, facilitating researchers in accelerating therapeutic discoveries. On February 26, Telesis Bio Inc. disclosed unaudited and preliminary financial results for the fourth fiscal quarter and fiscal year concluded on December 31, 2024. The report unveiled a total consolidated revenue projection of $27.5 million for the fiscal year 2023, showcasing an improvement from the $27.4 million generated in 2022. However, revenues in the fourth quarter are anticipated to reach $7 million, indicating a year-over-year decline of 26.3%.

Ocean Biomedical (NASDAQ: OCEA) made an announcement on December 5, 2023, regarding Jack Elias, its scientific co-founder, who had contributed to new discoveries featured in Immunity, a peer-reviewed journal. Ocean Biomedical highlighted that these findings shed light on the role of chitinase 3-like-1 (CHI3L1) in the progression of triple-negative breast cancer. Elias’s research demonstrated how CHI3L1 facilitated the stimulation of neutrophil production of NETs, which, in turn, hindered T cells from engaging with and eliminating the breast cancer tumor. Moreover, it was suggested that this tumor control mechanism could be applicable to other cancer types as well.

OneMedNet Corporation (NASDAQ: ONMD), the foremost provider of regulatory standard imaging real-world data curation, gained attention on February 12. The company announced its receipt of overwhelmingly positive feedback from participants at the 15th Annual SCOPE Summit. With over 4000 attendees from 27 countries representing 850 organizations, the summit convened to address challenges related to diversity, organization, and data access in clinical trials. It was disclosed that OneMedNet Corporation interacted with two of its existing customers during the event.

Kazia Therapeutics Limited (NASDAQ: KZIA), a prominent player in the field of oncology, made a significant announcement on February 21. The biotech company revealed the early completion of a two-part clinical trial after successfully reaching its primary endpoint. Initiated by the investigator, the trial focused on assessing paxasilib in combination with radiation therapy for individuals afflicted with brain metastases resulting from solid tumors with PI3K pathway mutations.